PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Multisociety Consensus Endorses Beta-Lactam Dose Individualization in Acutely Ill Patients

★ Must ReadBeta-Lactam Dose Individualization Consensus GuidanceACCP/ESCMID/IDSA/SCCM/SIDPsepsis and acute illnessbeta-lactam antibioticsTDMMIPD Infectious Disease / Antimicrobials

Background Information

New guidelines urge personalized beta-lactam dosing for acutely ill patients.

Beta-lactam antibiotics are crucial in treating acutely ill patients, but standard dosing may not ensure optimal efficacy and safety. Consensus guidance recommends individualized beta-lactam dosing based on patient-specific serum concentrations, addressing variability in drug levels. The guideline emphasizes personalized dosing for beta-lactams in severe infections, improving treatment outcomes by tailoring therapy to individual patient needs. Individualizing beta-lactam doses enhances effectiveness and safety for critically ill patients.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Barreto EF, McCreary EK, Pai Mangalore R, Tang Girdwood S, Arriola R, Bens C, Bonomo RA, Edginton AN, Hong LT, Huttner A, Koch BCP, Maranchick N, Neely MN, Peloquin CR, Rao GG, Roberts JA, Röhr AC, Scheetz MH, Schuetz AN, Yarnold PR, Zuluaga A, Rhodes NJ

Citation: Barreto EF, McCreary EK, Pai Mangalore R, et al. Consensus Guidance for Beta-Lactam Antibiotic Dose Individualization in Acutely Ill Patients: Endorsed by the American College of Clinical Pharmacy, European Society of Clinical Microbiology and Infectious Diseases, European Society of Clinical Microbiology and Infectious Diseases PK/PD of Anti-Infectives Study Group, Infectious Diseases Society of America, International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Society of Critical Care Medicine, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2026;46(8):e70181. doi:10.1002/phar.70181

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.